Last10K.com

Strongbridge Biopharma Plc (SBBP) SEC Filing 8-K Material Event for the period ending Friday, March 8, 2019

SEC Filings

SBBP Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

SBBP Annual Reports

SBBP Quarterly Reports

SBBP Corporate News

SBBP Merger Prospectus

Strongbridge Biopharma Plc

HISTORY TOOLS
CIK: 1634432 Ticker: SBBP

View differences made from one to another to evaluate Strongbridge Biopharma Plc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Strongbridge Biopharma Plc.

Continue

Assess how Strongbridge Biopharma Plc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Strongbridge Biopharma Plc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Strongbridge Biopharma Plc provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Ticker: SBBP
CIK: 1634432
Form Type: 8-K Corporate News
Accession Number: 0001104659-19-013519
Submitted to the SEC: Fri Mar 08 2019 7:45:46 AM EST
Accepted by the SEC: Fri Mar 08 2019
Period: Friday, March 8, 2019
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/sbbp/0001104659-19-013519.htm